Roche: Ocrelizumab: we are comfortable with our estimates

BUY – TOP PICKS, Fair Value CHF327 (+28%)
News published on October Tuesday 13, 2015
Share on

Roche held a conference call yesterday to present in more detail the perspective offered by ocrelizumab on the back of data presented at the ECTRIMS meeting. We are very comfortable with our estimates of USD3bn peak sales in 2022 and we stick to this objective.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities